On May 11, the Department of Commerce published the procedures by which pharmaceutical companies can apply for agreements to reduce Section 232 tariffs on imported patented drugs by moving manufacturing to the United States. Applications close on June 12. The tariff itself takes effect on July 31.
The timeline is deliberately compressed. Companies have roughly four weeks to commit to capital programs that will run for years, and the difference between filing and not filing is a tariff rate of 100 percent against a rate of 20 percent, or zero.
The Structure
The Section 232 action covers patented pharmaceutical products and their associated inputs, including active pharmaceutical ingredients and key starting materials. The headline rate is 100 percent, effective July 31, 2026.
Two forms of relief exist. A company that enters a qualifying agreement with the government and receives approval for a plan to onshore production of patented pharmaceuticals and associated ingredients pays 20 percent from September 29, 2026 through April 2, 2030. A company that holds both an onshoring agreement and an agreement to provide most-favored-nation pricing on its pharmaceutical products pays zero.
The tiering is deliberate. It converts a trade measure into a negotiating instrument that reaches both manufacturing location and domestic drug pricing, two policy objectives that have historically been pursued through separate and much slower channels.
What an Onshoring Agreement Commits a Company To
The application requires a plan, and a plan is an obligation. Approval rests on the credibility of a manufacturing buildout: sites, capital budgets, regulatory milestones, and dates. Companies that file will be measured against those dates for the duration of the relief period, which runs to April 2030.
For firms with existing US capacity and headroom to expand, this is a favorable trade. The capital was likely to be deployed anyway, and the tariff differential improves the return.
For firms whose patented portfolio is manufactured entirely offshore, the calculation is harder. Building API capacity in the United States is not a matter of leasing a building. Qualifying a new API site involves process validation, regulatory filings, and stability data. Three to five years from decision to commercial supply is a realistic range for a complex molecule, and the tariff arrives in July.
The most-favored-nation option adds a second layer. Zero tariff is attractive, and MFN pricing commitments compress revenue on the same products the manufacturing investment is meant to protect. Whether that trade is accretive depends on the geography of a company's revenue base and the price differentials it currently sustains between the United States and other developed markets.
The Input Problem
The measure covers active pharmaceutical ingredients and key starting materials, which is the thinnest part of the domestic supply chain. US capacity in fine chemicals, intermediates, and key starting materials contracted for two decades on cost grounds. Much of what remains is oriented toward low-volume, high-value work rather than the intermediate-scale production that commercial API manufacture requires.
A company can onshore final dosage form manufacturing relatively quickly. Onshoring the chemistry that feeds it is a different undertaking, and the specialized inputs several steps upstream frequently have no domestic producer at all. Approved onshoring plans that solve for fill-finish while leaving the upstream chain offshore will satisfy the letter of the agreement without changing the underlying dependency.
Strategic Implications
US contract manufacturing capacity becomes a contracted, scarce asset. Every approved onshoring plan requires physical capacity, and much of it will be leased rather than built. CDMOs with existing US sites, particularly those with sterile fill-finish and API capability, are positioned to sign long-duration agreements with creditworthy counterparties on favorable terms. Capacity that was competing on price in 2025 will be allocating on availability by 2027.
Mid-cap specialty pharma becomes an origination set. Companies with patented products, meaningful US revenue, and no domestic manufacturing face a cost structure that may not survive the transition. Some will be acquired by larger firms with US capacity to absorb the portfolio. Others will need capital to fund a buildout they cannot finance from cash flow. Both situations are transactable, and the June 12 deadline will separate the companies that have a plan from those that do not.
The intermediates and key starting materials layer is the underpriced link. Demand for domestic fine chemicals and intermediates is about to be created by regulatory action rather than by market growth. Existing US producers with expandable footprints and the ability to qualify under pharmaceutical standards have a demand outlook that does not depend on the commercial success of any single drug.
Regulatory and legal diligence now determines valuation. For any target in this sector, the terms of its onshoring agreement, the credibility of its milestone schedule, and its exposure under any MFN commitment are the material facts. A company that filed and cannot deliver faces a rate reset. That risk sits inside the agreement documents, not in the financial statements.
Outlook
Two dates govern the next four months. June 12 closes the application window and fixes which companies have optionality. September 29 is when the reduced rate becomes available to those that qualified, and by extension when the full 100 percent rate becomes the settled cost of doing business for those that did not.
Between those dates, the market will learn how many firms filed, how ambitious their commitments are, and how Commerce intends to police them. The construction that follows will be substantial, and it will be concentrated in a narrow set of sites, suppliers, and skill pools. Pricing that capacity correctly, before the July 31 effective date makes the shortage visible to everyone, is the opportunity in front of investors now.
Abbert Capital provides strategic advisory services across healthcare and pharmaceuticals, industrial infrastructure, and cross-border M&A, including acquisition lifecycle management from origination through integration. For further discussion of these developments and their implications, contact us.
The views expressed in this article are for informational purposes only and do not constitute investment advice. This material may contain forward-looking statements based on current expectations that involve risks and uncertainties.